212189-58-7Relevant academic research and scientific papers
Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin
Teno, Naoki,Gohda, Keigo,Wanaka, Keiko,Tsuda, Yuko,Sueda, Takuya,Yamashita, Yukiko,Otsubo, Tadamune
supporting information, p. 2339 - 2352 (2014/04/17)
In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is
HETEROCYCLIC COMPOUNDS FOR TREATING HELMINTH INFECTIONS
-
Page/Page column 41, (2013/02/28)
Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein L is (CR13aR13b)t,, CR14=CR14, C≡C, CR15aR15bX, XCR15aR15b, CO, O, S(O)p, NR
Derivatives of quinoline as inhibitors for MEK
-
Page/Page column 59, (2010/02/14)
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof. wherein: n is 0-1; X and Y are independently selected from -NH-, -O-, -S-, or -NR8- where R8 is alkyl of 1-6 carbon atoms and X may additionally comprise a CH2 group; R7 is a group (CH2)mR9 where m is 0,or an integer of from 1-3 and R9 is a substituted aryl group, an optionally substituted cycloalkyl ring of up to 10 carbon atoms, or an optionally substituted heterocyclic ring or an N-oxide of any nitrogen containing ring; R6 is a divalent cycloalkyl of 3 to 7 carbon atoms, which may be optionally further substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a divalent pyridinyl, pyimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally further substituted with one or more specified groups; R1, R2, R3 and R4 are each independently selected from hydrogen or various specified organic groups. Compounds are useful as pharmaceuticals for the inhibition of MEK activity.
